Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stoffel, M.
Right arrow Articles by et, al.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stoffel, M.
Right arrow Articles by et, al.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 42, Issue 6 937-940, Copyright © 1993 by American Diabetes Association

ARTICLES

Identification of glucokinase mutations in subjects with gestational diabetes mellitus

M Stoffel, KL Bell, CL Blackburn, KL Powell, TS Seo, J Takeda, N Vionnet, KS Xiang, M Gidh-Jain, SJ Pilkis and al. et
Howard Hughes Medical Institute, University of Chicago, Illinois 60637.

Recent studies have shown that mutations in the glucokinase gene on chromosome 7 can cause an autosomal dominant form of NIDDM with a variable clinical phenotype and onset during childhood. The variable clinical phenotype includes mild fasting hyperglycemia (i.e., a plasma glucose value of > 110 mg/dl, a value that is at least 2-3 SDs above normal), impaired glucose tolerance, gestational diabetes mellitus, as well as overt NIDDM as defined using National Diabetes Data Group or World Health Organization criteria. Because gestational diabetes mellitus was a clinical feature associated with glucokinase mutations, we have screened a group of women with gestational diabetes who also had a first-degree relative with diabetes mellitus for the presence of mutations in this gene. Among 40 subjects, we identified two mutations, suggesting a prevalence of approximately 5% in this group. Extrapolating from this result, the prevalence of glucokinase-deficient NIDDM among Americans may be approximately 1 in 2500.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
R. M. Watanabe, M. H. Black, A. H. Xiang, H. Allayee, J. M. Lawrence, and T. A. Buchanan
Genetics of Gestational Diabetes Mellitus and Type 2 Diabetes
Diabetes Care, July 1, 2007; 30(Supplement_2): S134 - S140.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
J. Weng, M. Ekelund, M. Lehto, H. Li, G. Ekberg, A. Frid, A. Aberg, L. C. Groop, and K. Berntorp
Screening for MODY Mutations, GAD Antibodies, and Type 1 Diabetes- Associated HLA Genotypes in Women With Gestational Diabetes Mellitus
Diabetes Care, January 1, 2002; 25(1): 68 - 71.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1993 by the American Diabetes Association.